Crvenkova S - Search Results

1

Review of Lung Cancer Patient Characteristics and Treatment Strategies in the Pandemic Covid-19 Year.

Crvenkova S, Jakimovki D, Ristovski V. Crvenkova S, et al. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2023 Mar 29;44(1):105-115. doi: 10.2478/prilozi-2023-0012. Print 2023 Mar 1. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2023. PMID: 36987767 Free article.

2

Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience.

Crvenkova S, Krstevska V. Crvenkova S, et al. Prilozi. 2009 Dec;30(2):197-207. Prilozi. 2009. PMID: 20087260 Clinical Trial.

3

Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.

Crvenkova S, Ivkovski Lj, Dimovski A, Kaeva B. Crvenkova S, et al. Prilozi. 2012;33(1):303-11. Prilozi. 2012. PMID: 22983065

4

Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.

Risteski M, Crvenkova S, Atanasov Z, Isjanovska R. Risteski M, et al. Among authors: crvenkova s. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(3):49-61. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013. PMID: 24566015

5

Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.

Crvenkova S, Pesevska M. Crvenkova S, et al. J BUON. 2015 May-Jun;20(3):775-81. J BUON. 2015. PMID: 26214630 Free article. Clinical Trial.

6

Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma.

Kakasheva-Mazhenkovska L, Basheska N, Crvenkova S, Gordana P, Milenkova L, Janevska V, Serafimoski V. Kakasheva-Mazhenkovska L, et al. Among authors: crvenkova s. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1;38(1):63-73. doi: 10.1515/prilozi-2017-0009. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017. PMID: 28593886 Free article.

7

Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.

Crvenkova S. Crvenkova S. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020 Sep 1;41(2):29-36. doi: 10.2478/prilozi-2020-0030. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020. PMID: 33011694 Free article.

8

Osimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.

Crvenkova S, Popova M, Crvenkova L, Lazarevska A. Crvenkova S, et al. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024 Dec 12;45(3):77-84. doi: 10.2478/prilozi-2024-0025. Print 2024 Nov 1. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024. PMID: 39667003 Free article.

9

Prognostic Factors and Survival in Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy.

Crvenkova S. Crvenkova S. Open Access Maced J Med Sci. 2015 Mar 15;3(1):75-9. doi: 10.3889/oamjms.2015.003. Epub 2014 Dec 29. Open Access Maced J Med Sci. 2015. PMID: 27275200 Free PMC article.

10

Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated With Combination of Chemotherapy and Conformal Radiotherapy.

Crvenkova S. Crvenkova S. Open Access Maced J Med Sci. 2018 Dec 11;6(12):2323-2327. doi: 10.3889/oamjms.2018.490. eCollection 2018 Dec 20. Open Access Maced J Med Sci. 2018. PMID: 30607184 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters